Status:
COMPLETED
Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis
Lead Sponsor:
Dr. Reddy's Laboratories Limited
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
This study will compare the plasma pharmacokinetic profile and the change in disease activity score in patients with active rheumatoid arthritis following treatment with two 1000 mg doses of DRL\_RI o...
Eligibility Criteria
Inclusion
- Male or female patients, 18 to 65 years of age
- Diagnosis of RA, according to ACR criteria (1987), of at least 6 months duration
- At randomization, tender joint count ≥ 6 and swollen joint count ≥ 6
- Evidence of at least moderate disease activity
- Patients receiving oral or parenteral MTX with a dose of 15 to 25 mg per week when given alone or 10 to 25 mg per week in combination with additional non-biologic DMARD(s) for at least 6 months and on stable dose for at least 3 months
- Patients must be on a stable dose of folic acid or equivalent (≥5 mg per week)
- Chest X-ray not suggestive of any lung infections including pulmonary tuberculosis (TB)
- Contraception required per protocol
Exclusion
- Prior therapy with
- Rituximab, abatacept, tocilizumab, anakinra or an agent/antibody targeting CD20, CD19 or B cells
- Tumor necrosis factor (TNF) alfa antagonists or other biologic DMARDs
- Other prior or concurrent therapies may also be excluded
- Any clinically relevant abnormality detected on screening history, physical examination, clinical laboratory, chest X-ray, or electrocardiogram (ECG), other than values consistent with RA
- Evidence of active, suspected or inadequately treated TB
- Positive serological test for hepatitis C virus antibodies, hepatitis B surface antigen, hepatitis B core antibody, or human immunodeficiency virus
- History of cardiovascular disease, history of stroke, or uncontrolled hypertension
- History of lymphoproliferative disease or organ allograft
- History of cancer (except for in situ cancer, excised, or limited stage, curatively treated cancer with no sign of disease for \>5 years)
- History of allergy (medication history) to any of the compounds used in the study
- Pregnant or lactating women or women planning to become pregnant during the study
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 5 2017
Estimated Enrollment :
276 Patients enrolled
Trial Details
Trial ID
NCT02296775
Start Date
November 1 2014
End Date
October 5 2017
Last Update
January 13 2020
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Gurunank Care Hospital
Hyderabad, Andhra Pradesh, India, 500020
2
Care Hospitals
Hyderabad, Andhra Pradesh, India, 500034
3
Krishna Institute of Medical Sciences Ltd.
Secunderabad, Andhra Pradesh, India, 500003
4
Yashoda Hospital
Secunderabad, Andhra Predesh, India, 500003